Daniel Liebler
Faculty Member
Last active: 2/15/2016

Efficacy of cetuximab in the treatment of Menetrier's disease.

Fiske WH, Tanksley J, Nam KT, Goldenring JR, Slebos RJ, Liebler DC, Abtahi AM, La Fleur B, Ayers GD, Lind CD, Washington MK, Coffey RJ
Sci Transl Med. 2009 1 (8): 8ra18

PMID: 20368185 · PMCID: PMC3638759 · DOI:10.1126/scitranslmed.3000320

Ménétrier's disease is a rare premalignant disorder of the stomach with no proven effective medical therapy. Increased epidermal growth factor receptor signaling has been implicated in the pathogenesis of Ménétrier's disease. We conducted a single-arm clinical trial with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor signaling, in nine individuals with clinically and histologically documented severe Ménétrier's disease that impaired quality of life to the extent that gastrectomy was being considered. Of the seven patients who completed the 1-month course of treatment, all showed statistically significant improvement both clinically (quality-of-life indices) and biochemically (increased parietal cell mass and gastric acidity). Furthermore, all seven patients who completed the 1-month trial elected to continue treatment, and four subsequently showed near-complete histological remission. Cetuximab should be considered as first-line therapy for Ménétrier's disease.

MeSH Terms (13)

Adult Aged Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antineoplastic Agents Cetuximab ErbB Receptors Female Gastritis, Hypertrophic Humans Male Middle Aged Quality of Life

Connections (5)

This publication is referenced by other Labnodes entities: